HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target

Benzinga · 10/15 17:27
HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 price target.